- Report
- July 2026
- 299 Pages
Global
From €5297EUR$5,850USD£4,519GBP
- Report
- October 2025
- 160 Pages
Global
From €2861EUR$3,160USD£2,441GBP
€3577EUR$3,950USD£3,051GBP
- Report
- June 2026
- 189 Pages
Global
From €3210EUR$3,545USD£2,738GBP
€3567EUR$3,939USD£3,042GBP
- Report
- June 2026
- 197 Pages
Global
From €3210EUR$3,545USD£2,738GBP
€3567EUR$3,939USD£3,042GBP
- Report
- February 2026
- 250 Pages
Global
From €4066EUR$4,490USD£3,468GBP
- Report
- February 2026
- 250 Pages
Global
From €4066EUR$4,490USD£3,468GBP
- Report
- February 2026
- 306 Pages
Global
From €2264EUR$2,500USD£1,931GBP
- Report
- February 2026
- 250 Pages
Global
From €4066EUR$4,490USD£3,468GBP
- Report
- February 2026
- 250 Pages
Global
From €4066EUR$4,490USD£3,468GBP
- Report
- July 2026
- 389 Pages
Global
From €5297EUR$5,850USD£4,519GBP
- Report
- January 2026
- 185 Pages
Global
From €4075EUR$4,500USD£3,476GBP
- Report
- July 2025
- 350 Pages
Global
From €4481EUR$4,949USD£3,823GBP
- Report
- October 2025
- 160 Pages
Global
From €2861EUR$3,160USD£2,441GBP
€3577EUR$3,950USD£3,051GBP
- Report
- August 2025
- 200 Pages
United States
From €2255EUR$2,490USD£1,923GBP
- Report
- May 2025
- 200 Pages
Global
From €2255EUR$2,490USD£1,923GBP
- Report
- August 2024
- 200 Pages
Global
From €2255EUR$2,490USD£1,923GBP
- Report
- June 2025
- 150 Pages
Global
From €3396EUR$3,750USD£2,896GBP
- Clinical Trials
- April 2025
- 220 Pages
Global
From €2264EUR$2,500USD£1,931GBP
- Report
- December 2024
- 171 Pages
Global
From €3577EUR$3,950USD£3,051GBP
- Report
- September 2024
- 343 Pages
Global
From €7199EUR$7,950USD£6,141GBP

Chronic Obstructive Pulmonary Disease (COPD) is a progressive lung disease that affects millions of people worldwide. It is characterized by difficulty breathing, coughing, and wheezing. COPD is typically treated with a combination of medications, including bronchodilators, inhaled corticosteroids, and antibiotics. The COPD drug market is a subset of the larger respiratory drug market, which includes drugs used to treat asthma, allergies, and other respiratory conditions.
The COPD drug market is highly competitive, with a variety of companies offering different types of medications. Some of the major players in the market include GlaxoSmithKline, AstraZeneca, Boehringer Ingelheim, Novartis, and Merck. These companies offer a range of COPD medications, including bronchodilators, inhaled corticosteroids, and antibiotics. Other companies, such as Teva Pharmaceuticals and Mylan, also offer generic versions of these medications. Show Less Read more